Qrons (QRON) Float Percentage Of Total Shares Outstanding : 25.86% (As of Jun. 06, 2024)

View and export this data going back to 2017. Start your Free Trial

What is Qrons Float Percentage Of Total Shares Outstanding?

Float percentage of total shares outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Qrons's float shares is 3.53 Mil. Qrons's total shares outstanding is 13.65 Mil. Qrons's float percentage of total shares outstanding is 25.86%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Qrons's Insider Ownership is 0.00%.

Institutional Ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Qrons's Institutional Ownership is 0.00%.

Qrons Float Percentage Of Total Shares Outstanding Calculation

It is the percentage of float shares out of the total shares outstanding.

Qrons's Float Percentage of Total Shares Outstanding for today is calculated as follows:

Float Percentage of Total Shares Outstanding	=	Float Shares	/	Total Shares Outstanding
	=	3.53	/	13.65
	=	25.86%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Qrons (QRON) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Qrons Inc (OTCPK:QRON) » Definitions » Float Percentage Of Total Shares Outstanding

Comparable Companies

Traded in Other Exchanges

N/A

Address

28-10 Jackson Avenue, No. 26N, Long Island City, New York, NY, USA, 11101

Website

https://www.qrons.com

Qrons Inc is a biotechnology company developing advanced cell-based solutions to combat neuronal injuries with a laser focus on traumatic brain injuries. The technology would treat a wide range of neurodegenerative diseases. The treatment integrates proprietary, engineered mesenchymal stem cells, 3D printable scaffolding, smart materials, and a novel delivery system. The firm has two product candidates, QS100TM for treating penetrating brain injuries and QS200TM, for treating concussions and other diffused axonal injuries.

Executives

John N Bonfiglio	officer: Chief Operating Officer	C/O MICROLIN BIO, INC., NEW YORK NY 10022
Jonah Meer	director, 10 percent owner, officer: CEO, CFO and Secretary	28-10 JACKSON AVENUE, #26N, LONG ISLAND CITY NY 11101
Ido Merfeld	director, 10 percent owner, officer: President	153 HAGILBOA STREET, NIRIT L3 44805